Anixa Biosciences Extends and Expands its Collaboration with New Jersey Urology

SAN JOSE, Calif., April 11, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it has extended and expanded its collaboration with New Jersey Urology, LLC ("NJU").  Pursuant to the extension, NJU will continue to provide patient samples for Anixa's ongoing Cchek™ early cancer detection study.  Further, the collaboration has been expanded to include support of clinical validation of Anixa's Cchek™ Prostate Cancer Confirmation test with Anixa's commercialization partner, ResearchDx.

Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)

Dr. Adam Perzin, who will continue to serve as the Principal Investigator at NJU for the study, stated, "We're excited about expanding our collaboration and helping Anixa towards commercialization of this test, as the PSA test for prostate cancer is not ideal."

"NJU continues to be a key collaborator in the development of Cchek™, our artificial intelligence driven liquid biopsy for early cancer detection, and we are pleased that this collaboration has been extended," stated Dr. Amit Kumar, CEO of Anixa.  "Further, we look forward to NJU's participation as we begin the clinical validation phase of Cchek™ in preparation for the commercial launch of our Cchek™ Prostate Cancer Confirmation test in the third quarter of this year," added Dr. Kumar.

NJU, through its April 2018 merger with Delaware Valley Urology, has been a collaborator of Anixa Biosciences' since March 2017.  NJU is the largest urology group in the United States, with nearly 100 physicians practicing at more than 40 locations within the state of New Jersey focusing on the advanced diagnosis and treatment of urological conditions including benign prostate conditions and prostate cancer. 

About Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.  Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.  It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy.  It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.  Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.  Additional information is available at

Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. 


Cision View original content to download multimedia:

SOURCE Anixa Biosciences, Inc.